Optimizing regional infusion treatment strategies for melanoma of the extremities

Andrew Coleman, Christina K. Augustine, Georgia Beasley, Gretchen Sanders, Douglas Tyler

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The incidence of malignant melanoma is increasing faster than any other cancer. In cases of recurrent melanoma confined to the extremities, hyperthermic isolated limb perfusion and isolated limb infusion provide a way to isolate the extremity and deliver a dose of chemotherapy several orders of magnitude higher than would be tolerated systemically. Although complete response rates of up to 80% for hyperthermic isolated limb perfusion and 44% for isolated limb infusion have been observed, there is still room for improvement and standardization in these two procedures in an attempt to optimize response while minimizing toxicity. Currently, new chemotherapy agents and small-molecule inhibitors are being investigated as a means of overcoming chemoresistance and improving response rates. In patients with advanced cutaneous disease confined to the extremities, evaluation of these new therapies can be very informative, as tissue acquisition at multiple treatment time points is easy owing to the superficial and multifocal nature of the disease. Through studying the biomolecular and genetic alterations in tumor tissue in response to these new therapies, genetically customized treatment regimens in which tumor resistance and sensitivity is predicted and treatment strategy is optimized before treatment begins may soon be available. Progress in regional therapy will prove not only beneficial for patients with disease confined to an extremity, but may also provide insight into developing novel treatment strategies for patients with systemic disease for whom current disease management options are poor.

Original languageEnglish (US)
Pages (from-to)1599-1609
Number of pages11
JournalExpert Review of Anticancer Therapy
Volume9
Issue number11
DOIs
StatePublished - Nov 2009
Externally publishedYes

Fingerprint

Melanoma
Extremities
Therapeutics
Perfusion
Drug Therapy
Neoplasms
Disease Management
Skin Diseases
Incidence

Keywords

  • ADH-1
  • Bevacizumab
  • Butathione sulfixime
  • Dasatinib
  • Hyperthermic isolated limb perfusion
  • IFN-γ
  • In-transit melanoma
  • Isolated limb infusion
  • Melanoma
  • Melphalan
  • O6-benzylguanine
  • Regional chemotherapy
  • Satellitosis
  • Sorafenib
  • Temozolomide
  • TNF-α

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Optimizing regional infusion treatment strategies for melanoma of the extremities. / Coleman, Andrew; Augustine, Christina K.; Beasley, Georgia; Sanders, Gretchen; Tyler, Douglas.

In: Expert Review of Anticancer Therapy, Vol. 9, No. 11, 11.2009, p. 1599-1609.

Research output: Contribution to journalArticle

Coleman, Andrew ; Augustine, Christina K. ; Beasley, Georgia ; Sanders, Gretchen ; Tyler, Douglas. / Optimizing regional infusion treatment strategies for melanoma of the extremities. In: Expert Review of Anticancer Therapy. 2009 ; Vol. 9, No. 11. pp. 1599-1609.
@article{350310a725894101b24cbcf5962d192e,
title = "Optimizing regional infusion treatment strategies for melanoma of the extremities",
abstract = "The incidence of malignant melanoma is increasing faster than any other cancer. In cases of recurrent melanoma confined to the extremities, hyperthermic isolated limb perfusion and isolated limb infusion provide a way to isolate the extremity and deliver a dose of chemotherapy several orders of magnitude higher than would be tolerated systemically. Although complete response rates of up to 80{\%} for hyperthermic isolated limb perfusion and 44{\%} for isolated limb infusion have been observed, there is still room for improvement and standardization in these two procedures in an attempt to optimize response while minimizing toxicity. Currently, new chemotherapy agents and small-molecule inhibitors are being investigated as a means of overcoming chemoresistance and improving response rates. In patients with advanced cutaneous disease confined to the extremities, evaluation of these new therapies can be very informative, as tissue acquisition at multiple treatment time points is easy owing to the superficial and multifocal nature of the disease. Through studying the biomolecular and genetic alterations in tumor tissue in response to these new therapies, genetically customized treatment regimens in which tumor resistance and sensitivity is predicted and treatment strategy is optimized before treatment begins may soon be available. Progress in regional therapy will prove not only beneficial for patients with disease confined to an extremity, but may also provide insight into developing novel treatment strategies for patients with systemic disease for whom current disease management options are poor.",
keywords = "ADH-1, Bevacizumab, Butathione sulfixime, Dasatinib, Hyperthermic isolated limb perfusion, IFN-γ, In-transit melanoma, Isolated limb infusion, Melanoma, Melphalan, O6-benzylguanine, Regional chemotherapy, Satellitosis, Sorafenib, Temozolomide, TNF-α",
author = "Andrew Coleman and Augustine, {Christina K.} and Georgia Beasley and Gretchen Sanders and Douglas Tyler",
year = "2009",
month = "11",
doi = "10.1586/ERA.09.126",
language = "English (US)",
volume = "9",
pages = "1599--1609",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Optimizing regional infusion treatment strategies for melanoma of the extremities

AU - Coleman, Andrew

AU - Augustine, Christina K.

AU - Beasley, Georgia

AU - Sanders, Gretchen

AU - Tyler, Douglas

PY - 2009/11

Y1 - 2009/11

N2 - The incidence of malignant melanoma is increasing faster than any other cancer. In cases of recurrent melanoma confined to the extremities, hyperthermic isolated limb perfusion and isolated limb infusion provide a way to isolate the extremity and deliver a dose of chemotherapy several orders of magnitude higher than would be tolerated systemically. Although complete response rates of up to 80% for hyperthermic isolated limb perfusion and 44% for isolated limb infusion have been observed, there is still room for improvement and standardization in these two procedures in an attempt to optimize response while minimizing toxicity. Currently, new chemotherapy agents and small-molecule inhibitors are being investigated as a means of overcoming chemoresistance and improving response rates. In patients with advanced cutaneous disease confined to the extremities, evaluation of these new therapies can be very informative, as tissue acquisition at multiple treatment time points is easy owing to the superficial and multifocal nature of the disease. Through studying the biomolecular and genetic alterations in tumor tissue in response to these new therapies, genetically customized treatment regimens in which tumor resistance and sensitivity is predicted and treatment strategy is optimized before treatment begins may soon be available. Progress in regional therapy will prove not only beneficial for patients with disease confined to an extremity, but may also provide insight into developing novel treatment strategies for patients with systemic disease for whom current disease management options are poor.

AB - The incidence of malignant melanoma is increasing faster than any other cancer. In cases of recurrent melanoma confined to the extremities, hyperthermic isolated limb perfusion and isolated limb infusion provide a way to isolate the extremity and deliver a dose of chemotherapy several orders of magnitude higher than would be tolerated systemically. Although complete response rates of up to 80% for hyperthermic isolated limb perfusion and 44% for isolated limb infusion have been observed, there is still room for improvement and standardization in these two procedures in an attempt to optimize response while minimizing toxicity. Currently, new chemotherapy agents and small-molecule inhibitors are being investigated as a means of overcoming chemoresistance and improving response rates. In patients with advanced cutaneous disease confined to the extremities, evaluation of these new therapies can be very informative, as tissue acquisition at multiple treatment time points is easy owing to the superficial and multifocal nature of the disease. Through studying the biomolecular and genetic alterations in tumor tissue in response to these new therapies, genetically customized treatment regimens in which tumor resistance and sensitivity is predicted and treatment strategy is optimized before treatment begins may soon be available. Progress in regional therapy will prove not only beneficial for patients with disease confined to an extremity, but may also provide insight into developing novel treatment strategies for patients with systemic disease for whom current disease management options are poor.

KW - ADH-1

KW - Bevacizumab

KW - Butathione sulfixime

KW - Dasatinib

KW - Hyperthermic isolated limb perfusion

KW - IFN-γ

KW - In-transit melanoma

KW - Isolated limb infusion

KW - Melanoma

KW - Melphalan

KW - O6-benzylguanine

KW - Regional chemotherapy

KW - Satellitosis

KW - Sorafenib

KW - Temozolomide

KW - TNF-α

UR - http://www.scopus.com/inward/record.url?scp=71949107008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71949107008&partnerID=8YFLogxK

U2 - 10.1586/ERA.09.126

DO - 10.1586/ERA.09.126

M3 - Article

VL - 9

SP - 1599

EP - 1609

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 11

ER -